Patent details

Basic Information

Publication number:

EP3302485

PCT Application Number:

US2016034861

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP168041770

PCT Publication Number:

WO2016196385

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

French Title of Invention:

CERDULATINIB POUR LE TRAITEMENT DES AFFECTIONS MALIGNES À CELLULES B

German Title of Invention:

CERDULATINIB ZUR BEHANDLUNG VON B-ZELL-MALIGNOMEN

SPC Number:

Dates

Filing date:

27/05/2016

Grant date:

12/07/2023

EP Publication Date:

11/04/2018

PCT Publication Date:

08/12/2016

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

12/07/2023

EP B1 Publication Date:

12/07/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

27/05/2024

Expiration date:

27/05/2036

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

05/07/2023

 

 

Name:

Alexion Pharmaceuticals, Inc.

Address:

121 Seaport Boulevard, Boston, MA 02210, United States (US)

Inventor

1

Name:

LEEDS, Janet

Address:

United States (US)

2

Name:

COFFEY, Gregory

Address:

United States (US)

3

Name:

PANDEY, Anjali

Address:

United States (US)

Priority

1

Priority Number:

201562168530 P

Priority Date:

29/05/2015

Priority Country:

United States (US)

2

Priority Number:

201562263582 P

Priority Date:

04/12/2015

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/506; A61P 35/02;

Publication

European Patent Bulletin

Issue number:

202328

Publication date:

12/07/2023

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages